Skip to content
Search

Latest Stories

More Covid restrictions could turn future bleak, says Caffe Nero

More Covid restrictions could turn future bleak, says Caffe Nero

IMPOSITION of further restrictions to curb the spread of Covid-19 in the UK could put Caffe Nero’s future in doubt, the company’s top officials said.

Caffe Nero’s directors including founder Gerry Ford said a fresh wave of temporary closures and a legal challenge by landlords to restructuring of the business cast “material uncertainties” over its future, The Telegraph reported.


Its landlords challenged proposals to renegotiate rents after knowing that the billionaire Issa brothers made an eleventh-hour bid to take control of the company last November.

Caffe Nero’s auditors, EY, has also raised concerns over the company’s future due to uncertainty around the outcome of the restructuring and when trading would return to pre-pandemic levels.

The chain’s top executives remained worried about the possibility of a third wave of coronavirus, and the impact it would have on trade due to subsequent lockdown. In case of another lockdown, the company would find it difficult to pay off its £390 million of debt, they said.

Health secretary Matt Hancock said recently that the government is "absolutely open" to delaying the final lifting of England's Covid lockdown on June 21, if necessary.

The Issa brothers, who acquired Asda for £6.8 billion earlier this year, have bought £140m of Caffe Nero’s debts, putting them in a strong position to seize control of the business, if the chain defaults on its debt.

Meanwhile, the chain had just managed to meet the May 31 deadline to file its annual accounts and pledged to meet all of its banking covenants.

“As is the case for all other retail and hospitality businesses, we certainly hope the Government will not impose additional lockdowns as that would create further uncertainty,” a Caffe Nero spokesman said.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less